

Medvet Laboratories offers a comprehensive range of cost-effective health and safety services delivered by qualified and experienced professionals. These services include on-site health testing services and a range of laboratory based pathology testing services. The commercial and occupational health testing services are tailored to your individual requirements. Medvet Laboratories major commercial pathology services are detailed below.

Immunology

The diagnostic laboratory of Human Immunology is the largest diagnostic Immunology laboratory in the State and one of the largest in Australia. It provides an immunopathology service to metropolitan and rural areas in South Australia. In addition, it is a major referral laboratory to both public and private pathology laboratories within the State and interstate.

The laboratory offers a range of specialised diagnostic immunology services in flow cytometry and protein chemistry for the assessment of the immune function and diagnosis of malignant disease; allergy diagnosis; detection of autoantibodies for the diagnosis of autoimmune disease; and molecular testing for malignant disease, autoimmune disease and drug metabolism. The laboratory also supports research and training with interests and expertise in autoimmunity, immunodeficiency, allergy and pharmacogenomics; and support of medical registrar training.

Transfusion Medicine

The Transfusion Medicine Unit (TMU) performs pre-transfusion compatibility testing and screening tests to enable the safe transfusion of a range of blood products and components. Testing that is performed also helps diagnose and prevent haemolytic disease of the newborn, and problems associated with autoimmune haemolysis.

With the State Adult Haemophilia and Thalassaemia Centres also based at our facility the TMU is intimately involved in patient care for these groups in providing tailored product protocols in liaison with ARCBS. The TMU manages massive transfusion and critical bleeding episodes in close co-operation with retrieval, emergency medicine and intensive care specialists.

Haematology

The Haematology Unit is comprised of 7 Research groups whose work ranges from basic in nature (Cell death and differentiation, Lymphangiogenesis) through to translational (Acute and Chronic Myeloid Research, Myeloma Research and application of haemopoietic and mesenchymal stem cells). The operational capabilities include the development of novel biochemical assays to predict therapeutic efficacy of agents such as the anti-leukaemia drug, imatinib.

The Haematology unit has developed numerous pre-clinical small animal models to examine myeloma, stroke and haemopoietic reconstitution. In addition, large animal models for cell based therapies for heart disease, dental and long bone repair have been developed. The Division is also expert in numerous molecular and cell-based assays/ technologies such as novel whole blood processing, molecular disease monitoring, cryogenic banking of tissues, flow cytometry and cell imaging.

Therapeutic Products

The Therapeutic Products Facility (TPF) provides an environment where cellular based therapies can be manufactured to the highest standards of purity, integrity, safety and strength. To ensure this the facility has implemented a quality system which incorporates elements required by the TGA, APVMA, NATA, and ISO 9001.

The facility is licensed by the TGA for the manufacture of haemopoietic progenitor cells from blood and bone marrow, for the manufacture of autologous chondrocytes for implantation and for the culture of keratinocytes for the treatment of burns patients. A License for the manufacture of autologous fibrin sealant is pending. In addition the facility is licensed by the APVMA for the contract manufacture of equine mesenchymal cells for tendon repair.

